Table 3 Early postoperative morbidity.

From: Pulmonary effects of dexmedetomidine infusion in thoracic aortic surgery under hypothermic circulatory arrest: a randomized placebo-controlled trial

Parameters

Control group (n = 25)

Dexmedetomidine group (n = 26)

P value

Major morbidity endpoints in 30 days

Myocardial infarction

0

0

 

Atrial fibrillation

4 (16.0)

2 (7.7)

0.419

Delirium

9 (36.0)

9 (34.6)

0.918

Cerebrovascular attack

0

1 (4)

> 0.999

ARDS

4 (16.0)

0 (0.0)

0.051

GI tract ischemia or hemorrhage

2 (8.0)

1(3.9)

0.610

Acute kidney injury

7 (28.0)

4 (15.4)

0.274

Renal replacement therapy

3 (12.0)

0 (0.0)

0.110

Deep sternal infection

0

0

 

Mortality

2 (8.0)

0 (0.0)

0.235

Ventilator support after surgery (h)

16.00 [10.50–22.50]

16.00 [8.35–21.38]

0.977

Prolonged ventilator support > 24 h

6(24.0)

4 (15.4)

0.499

Re-intubation

1(4.0)

1 (3.9)

> 0.999

Intensive care unit stay (h)

58 (47.0–75.0)

54 (46.8–97.3)

0.985

Hospital stay (day)

18 (12.0–25.0)

15 (11–20.8)

0.565

  1. Values are shown in number of patients (percentage), mean ± standard deviation or median (interquartile range). ARDS acute respiratory distress syndrome, GI gastrointestinal.